Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588818 | 0.93 | ABCG2 (0.34) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL13254291 | 0.88 | ALDH1A1 (0.32) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3593530 | 0.86 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3593533 | 0.86 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3600917 | 0.86 | SIGMAR1 (0.33) | ABCG2ABCB1SIGMAR1ALDH1A1LMNA | |
| SCHEMBL3602945 | 0.85 | ALDH1A1 (0.34) | KMT2AABCG2ABCB1METSIGMAR1 | |
| SCHEMBL3604171 | 0.83 | ABCB1 (0.43) | ABCG2ABCB1ALDH1A1LMNAMAPK1 | |
| SCHEMBL3595511 | 0.83 | BCHE (0.36) | POLBKMT2ALMNAMAPK1 | |
| SCHEMBL3589591 | 0.81 | MAPK1 (0.35) | POLBKMT2AABCB1ALDH1A1MAPK1 | |
| SCHEMBL3589259 | 0.81 | ALDH1A1 (0.35) | KMT2AMETSIGMAR1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | POLB 4635/4885KMT2A 4721/4885ABCG2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.